Haussier
Johnson & Johnson's Q2 earnings beat expectations; stock price target raised to $261.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Johnson & Johnson reported strong second-quarter results, with earnings per share (EPS) of $2.90, surpassing analyst expectations. The company also raised its full-year 2026 revenue guidance to approximately $101.1 billion, marking a significant milestone. Additionally, J&J announced a $750 million restructuring plan to streamline its pharmaceutical supply chain.
Points clés
- Guggenheim maintains 'Buy' rating and $270 price target after Q2 earnings beat.
- Bernstein raises price target to $261 following strong Q2 performance.
- J&J announces $750 million restructuring to streamline pharmaceutical supply chain.
- DePuy Synthes acquires Expanding Innovations to enhance spine surgery technology.
Sources
- Guggenheim reiterates Johnson & Johnson stock rating on Q2 beatInvesting.com · July 16, 2026
- Bernstein raises Johnson & Johnson stock price target on earnings beatInvesting.com · July 16, 2026
- J&J Spends Up to $750M to Restructure Drug Supply ChainPharmaSource · July 16, 2026
- Johnson & Johnson Press ReleasesJohnson & Johnson · July 16, 2026
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
